Role of AMP-activated protein kinase in the metabolic syndrome and in heart disease

FEBS Letters

Volumn 582, Issue 1, 2008, Pages 81-89

  Hardie, D Grahame ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

AMP activated protein kinase; Diabetes; Metabolic syndrome; Metformin; Thiazolidinedione; Ventricular pre excitation

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADIPOCYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; PHENFORMIN; PIOGLITAZONE; ROSIGLITAZONE;

DIABETES MELLITUS; ENZYME ACTIVATION; EUKARYOTE; GENE MUTATION; HEART DISEASE; HUMAN; LACTIC ACIDOSIS; MAMMAL; METABOLIC DISORDER; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SHORT SURVEY; WOLFF PARKINSON WHITE SYNDROME;

ANIMALS; ENZYME ACTIVATORS; HEART DISEASES; HUMANS; METABOLIC SYNDROME X; MULTIENZYME COMPLEXES; MUTATION; PROTEIN-SERINE-THREONINE KINASES;

EID: 37349041710     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2007.11.018     Document Type: Short Survey

References (86)

1. Hu F.B., Manson J.E., Stampfer M.J., Colditz G., Liu S., Solomon C.G., and Willett W.C. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N. Engl. J. Med. 345 (2001) 790-797
2. Sriwijitkamol A., et al. Effect of acute exercise on AMPK signaling in skeletal muscle of subjects with type 2 diabetes: a time-course and dose-response study. Diabetes 56 (2007) 836-848
3. Hardie D.G. AMP-activated protein kinase as a drug target. Annu. Rev. Pharmacol. Toxicol. 47 (2007) 185-210
4. Celenza J.L., and Carlson M. A yeast gene that is essential for release from glucose repression encodes a protein kinase. Science 233 (1986) 1175-1180
5. Apfeld J., O'Connor G., McDonagh T., Distefano P.S., and Curtis R. The AMP-activated protein kinase AAK-2 links energy levels and insulin-like signals to lifespan in C. elegans. Genes Dev. 18 (2004) 3004-3009
6. Narbonne P., and Roy R. Inhibition of germline proliferation during C. elegans dauer development requires PTEN, LKB1 and AMPK signalling. Development 133 (2006) 611-619
7. Thelander M., Olsson T., and Ronne H. Snf1-related protein kinase 1 is needed for growth in a normal day-night light cycle. EMBO J. 23 (2004) 1900-1910
8. Suter M., Riek U., Tuerk R., Schlattner U., Wallimann T., and Neumann D. Dissecting the role of 5′-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase. J. Biol. Chem. 281 (2006) 32207-32216
9. Hawley S.A., Boudeau J., Reid J.L., Mustard K.J., Udd L., Makela T.P., Alessi D.R., and Hardie D.G. Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2 (2003) 28
10. Woods A., et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol. 13 (2003) 2004-2008
11. Lizcano J.M., et al. LKB1 is a master kinase that activates 13 protein kinases of the AMPK subfamily, including the MARK/PAR-1 kinases. EMBO J. 23 (2004) 833-843
12. Sakamoto K., Goransson O., Hardie D.G., and Alessi D.R. Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR. Am. J. Physiol. Endocrinol. Metab. 287 (2004) E310-E317
13. C. FEBS Lett. 377 (1995) 421-425
14. Sanders M.J., Grondin P.O., Hegarty B.D., Snowden M.A., and Carling D. Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem. J. 403 (2007) 139-148
15. Hancock C.R., Janssen E., and Terjung R.L. Contraction-mediated phosphorylation of AMPK is lower in skeletal muscle of adenylate kinase-deficient mice. J. Appl. Physiol. 100 (2006) 406-413
16. Hawley S.A., Pan D.A., Mustard K.J., Ross L., Bain J., Edelman A.M., Frenguelli B.G., and Hardie D.G. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2 (2005) 9-19
17. 2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab. 2 (2005) 21-33
18. 2+/calmoldulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J. Biol. Chem. 280 (2005) 29060-29066
19. 2+/calmodulin-dependent protein kinase kinase beta. J. Biol. Chem. 273 (1998) 31880-31889
20. 2+ in T lymphocytes. J. Exp. Med. 203 (2006) 1665-1670
21. 2+/calmodulin-dependent protein kinase kinase beta. Mol. Cell Biol. 26 (2006) 5933-5945
22. Momcilovic M., Hong S.P., and Carlson M. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J. Biol. Chem. 281 (2006) 25336-25343
23. Sakamoto K., McCarthy A., Smith D., Green K.A., Hardie D.G., Ashworth A., and Alessi D.R. Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J. 24 (2005) 1810-1820
24. Sakamoto K., et al. Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKa2 but not AMPKa1. Am. J. Physiol. Endocrinol. Metab. 290 (2006) E780-E788
25. Jensen T.E., Rose A.J., Hellsten Y., Wojtaszewski J.F., and Richter E.A. Caffeine-induced Ca2+ release increases AMPK-dependent glucose uptake in rodent soleus muscle. Am. J. Physiol. Endocrinol. Metab. 293 (2007) 286-292
26. Jensen T.E., Rose A.J., Jorgensen S.B., Brandt N., Schjerling P., Wojtaszewski J.F., and Richter E.A. Possible CaMKK-dependent regulation of AMPK phosphorylation and glucose uptake at the onset of mild tetanic skeletal muscle contraction. Am. J. Physiol. Endocrinol. Metab. 292 (2007) E1308-E1317
27. Minokoshi Y., Kim Y.B., Peroni O.D., Fryer L.G., Muller C., Carling D., and Kahn B.B. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415 (2002) 339-343
28. Minokoshi Y., et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428 (2004) 569-574
29. Andersson U., Filipsson K., Abbott C.R., Woods A., Smith K., Bloom S.R., Carling D., and Small C.J. AMP-activated protein kinase plays a role in the control of food intake. J. Biol. Chem. 279 (2004) 12005-12008
30. Kola B., et al. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated Protein Kinase. J. Biol. Chem. 280 (2005) 25196-25201
31. Claret C., et al. AMPK is essential for energy homeostasis regulation and glucose-sensing by POMC and AgRP neurons. J. Clin. Invest. 117 (2007) 2325-2336
32. McCrimmon R.J., Fan X., Ding Y., Zhu W., Jacob R.J., and Sherwin R.S. Potential role for AMP-activated protein kinase in hypoglycemia sensing in the ventromedial hypothalamus. Diabetes 53 (2004) 1953-1958
33. Alquier T., Kawashima J., Tsuji Y., and Kahn B.B. Role of hypothalamic adenosine 5'-monophosphate-activated protein kinase in the impaired counterregulatory response induced by repetitive neuroglucopenia. Endocrinology 148 (2007) 1367-1375
34. Yamauchi T., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 6 (2002) 1288-1295
35. Tomas E., Tsao T.S., Saha A.K., Murrey H.E., Zhang C.C., Itani S.I., Lodish H.F., and Ruderman N.B. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc. Natl. Acad. Sci. USA 99 (2002) 16309-16313
36. Yamauchi T., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423 (2003) 762-769
37. Kurth-Kraczek E.J., Hirshman M.F., Goodyear L.J., and Winder W.W. 5' AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes 48 (1999) 1667-1671
38. Barnes K., et al. Activation of GLUT1 by metabolic and osmotic stress: potential involvement of AMP-activated protein kinase (AMPK). J. Cell Sci. 115 (2002) 2433-2442
39. Zheng D., MacLean P.S., Pohnert S.C., Knight J.B., Olson A.L., Winder W.W., and Dohm G.L. Regulation of muscle GLUT-4 transcription by AMP-activated protein kinase. J. Appl. Physiol. 91 (2001) 1073-1083
40. Mu J., Brozinick J.T., Valladares O., Bucan M., and Birnbaum M.J. A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol. Cell 7 (2001) 1085-1094
41. Jorgensen S.B., et al. Knockout of the alpha2 but not alpha1 5'-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranosidebut not contraction-induced glucose uptake in skeletal muscle. J. Biol. Chem. 279 (2004) 1070-1079
42. Treebak J.T., Birk J.B., Rose A.J., Kiens B., Richter E.A., and Wojtaszewski J.F. AS160 phosphorylation is associated with activation of {α}2{β}2{γ}1 but not {α}2{β}2{γ}3 AMPK trimeric complex in skeletal muscle during exercise in humans. Am. J. Physiol. Endocrinol. Metab. 292 (2006) E715-E722
43. Kramer H.F., et al. Distinct signals regulate AS160 phosphorylation in response to insulin, AICAR, and contraction in mouse skeletal muscle. Diabetes 55 (2006) 2067-2076
44. Lochhead P.A., Salt I.P., Walker K.S., Hardie D.G., and Sutherland C. 5-Aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes 49 (2000) 896-903
45. Koo S.H., et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437 (2005) 1109-1114
46. Unger R.H. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 144 (2003) 5159-5165
47. Corton J.M., Gillespie J.G., Hawley S.A., and Hardie D.G. 5-Aminoimidazole-4-carboxamide ribonucleoside: a specific method for activating AMP-activated protein kinase in intact cells?. Eur. J. Biochem. 229 (1995) 558-565
48. Woods A., Azzout-Marniche D., Foretz M., Stein S.C., Lemarchand P., Ferre P., Foufelle F., and Carling D. Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. Mol. Cell Biol. 20 (2000) 6704-6711
49. Merrill G.M., Kurth E., Hardie D.G., and Winder W.W. AICAR decreases malonyl-CoA and increases fatty acid oxidation in skeletal muscle of the rat. Am. J. Physiol. 273 (1997) E1107-E1112
50. Daval M., et al. Anti-lipolytic action of AMP-activated protein kinase in rodent adipocytes. J. Biol. Chem. 280 (2005) 25250-25257
51. Zong H., Ren J.M., Young L.H., Pypaert M., Mu J., Birnbaum M.J., and Shulman G.I. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc. Natl. Acad. Sci. USA 99 (2002) 15983-15987
52. Lowell B.B., and Shulman G.I. Mitochondrial dysfunction and type 2 diabetes. Science 307 (2005) 384-387
53. Inoki K., Zhu T., and Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115 (2003) 577-590
54. Harrington L.S., et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166 (2004) 213-223
55. Shah O.J., Wang Z., and Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 14 (2004) 1650-1656
56. Um S.H., et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431 (2004) 200-205
57. Fisher J.S., Gao J., Han D.H., Holloszy J.O., and Nolte L.A. Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin. Am. J. Physiol. 282 (2002) E18-E23
58. Song X.M., Fiedler M., Galuska D., Ryder J.W., Fernström M., Chibalin A.V., Wallberg-Henriksson H., and Zierath J.R. 5-Aminoimidazole-4-caboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice. Diabetologia 45 (2002) 56-65
59. Bergeron R., Previs S.F., Cline G.W., Perret P., Russell III R.R., Young L.H., and Shulman G.I. Effect of 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes 50 (2001) 1076-1082
60. Buhl E.S., et al. Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes 51 (2002) 2199-2206
61. Iglesias M.A., Ye J.M., Frangioudakis G., Saha A.K., Tomas E., Ruderman N.B., Cooney G.J., and Kraegen E.W. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes 51 (2002) 2886-2894
62. Zhou G., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108 (2001) 1167-1174
63. Hawley S.A., Gadalla A.E., Olsen G.S., and Hardie D.G. The anti-diabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51 (2002) 2420-2425
64. Wang D.S., Jonker J.W., Kato Y., Kusuhara H., Schinkel A.H., and Sugiyama Y. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J. Pharmacol. Exp. Ther. 302 (2002) 510-515
65. Shaw R.J., Lamia K.A., Vasquez D., Koo S.H., Bardeesy N., Depinho R.A., Montminy M., and Cantley L.C. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310 (2005) 1642-1646
66. Saha A.K., Avilucea P.R., Ye J.M., Assifi M.M., Kraegen E.W., and Ruderman N.B. Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem. Biophys. Res. Commun. 314 (2004) 580-585
67. Fryer L.G., Parbu-Patel A., and Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct pathways. J. Biol. Chem. 277 (2002) 25226-25232
68. Brunmair B., et al. Thiazolidinediones, like metformin, Inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?. Diabetes 53 (2004) 1052-1059
69. El-Mir M.Y., Nogueira V., Fontaine E., Averet N., Rigoulet M., and Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 275 (2000) 223-228
70. Owen M.R., Doran E., and Halestrap A.P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 348 (2000) 607-614
71. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270 (1995) 12953-12956
72. Kubota N., et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J. Biol. Chem. 281 (2006) 8748-8755
73. Nawrocki A.R., et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J. Biol. Chem. 281 (2006) 2654-2660
74. Bateman A. The structure of a domain common to archaebacteria and the homocystinuria disease protein. Trends Biochem. Sci. 22 (1997) 12-13
75. Scott J.W., Hawley S.A., Green K.A., Anis M., Stewart G., Scullion G.A., Norman D.G., and Hardie D.G. CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. J. Clin. Invest. 113 (2004) 274-284
76. Arad M., Seidman C.E., and Seidman J.G. AMP-activated protein kinase in the heart: role during health and disease. Circ. Res. 100 (2007) 474-488
77. Burwinkel B., Scott J.W., Buhrer C., van Landeghem F.K., Cox G.F., Wilson C.J., Hardie D.G., and Kilimann M.W. Fatal congenital heart glycogenosis caused by a recurrent activating R531Q mutation in the g2 subunit of AMP-activated protein kinase (PRKAG2), not by phosphorylase kinase deficiency. Am. J. Hum. Genet. 76 (2005) 1034-1049
78. Akman, H.O., et al. (2007) Fatal infantile cardiac glycogenosis with phosphorylase kinase deficiency and a mutation in the gamma-2 subunit of AMP-activated protein kinase. Ped. Res.
79. Daniel T.D., and Carling D. Functional analysis of mutations in the γ2 subunit of AMP-activated protein kinase associated with cardiac hypertrophy and Wolff-Parkinson-White syndrome. J. Biol. Chem. 277 (2002) 51017-51024
80. Townley R., and Shapiro L. Crystal structures of the adenylate sensor from fission yeast AMP-activated protein kinase. Science 315 (2007) 1726-1729
81. Wilson W.A., Hawley S.A., and Hardie D.G. The mechanism of glucose repression/derepression in yeast: SNF1 protein kinase is activated by phosphorylation under derepressing conditions, and this correlates with a high AMP:ATP ratio. Current Biol. 6 (1996) 1426-1434
82. Luptak I., et al. Aberrant activation of AMP-activated protein kinase remodels metabolic network in favor of cardiac glycogen storage. J. Clin. Invest. 117 (2007) 1432-1439
83. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356 (2007) 2457-2471
84. Bailey C.J., Wilcock C., and Day C. Effect of metformin on glucose metabolism in the splanchnic bed. Br. J. Pharmacol. 105 (1992) 1009-1013
85. Koepsell H., Lips K., and Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical Implications. Pharm. Res. 24 (2007) 1227-1251
86. Cool B., et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 3 (2006) 403-416